Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 20/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703219 | 0.92 | PDE3B (0.61) | PDE3BPDE3A | |
| SCHEMBL20702779 | 0.85 | PDE3B (0.69) | PDE3BPDE3A | |
| SCHEMBL20702944 | 0.83 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL29842880 | 0.83 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL22308882 | 0.83 | PDE3B (0.63) | PDE3BPDE3A | |
| SCHEMBL22317381 | 0.82 | PDE3B (0.68) | PDE3BPDE3A | |
| SCHEMBL20703467 | 0.82 | PDE3B (0.67) | PDE3BPDE3A | |
| SCHEMBL22307814 | 0.81 | PDE3B (0.61) | PDE3BPDE3A | |
| SCHEMBL22288427 | 0.81 | PDE3B (0.69) | PDE3BPDE3A | |
| SCHEMBL22305293 | 0.81 | PDE3B (0.59) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | claimed |
| EP-3661917-B1 | 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AG (DE) | 2022-05-11 | — | — | EP | claimed |
| US-20200247783-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | US | claimed |
| EP-3661917-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025554-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-13 | — | — | US | disclosed |
| EP-3661917-B1 | 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| US-20200247783-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | US | disclosed |
| WO-2020157199-A1 | ANNULATED DIHYDROPYRIDAZINONE COMPOUNDS AS ANTI-CANCER COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247783-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | US | disclosed |
| WO-2019025554-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885 |
| US-20200247783-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | PDE3B, PDE3A, PDE5A | PDE3B 1/4885PDE3A 2/4885 |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | PDE3B, PDE3A, PDE5A | PDE3B 1/4885PDE3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.